Drug intelligence / Profile preview

lidocaine topical system

Development stage: Approved
Lead developer: Scilex Holding
Modality: Small Molecules
Administration: Topical, Transdermal

Overview

ZTlido is a single-layer, drug-in-adhesive topical delivery system containing lidocaine, an amide local anesthetic. It is specifically formulated to provide equivalent lidocaine exposure to Lidoderm (lidocaine patch 5%) but at a lower concentration (1.8%). ZTlido is designed as a transdermal anesthetic for the treatment of pain associated with post-herpetic neuralgia (PHN) in adults. The system delivers lidocaine directly to the affected area, providing localized pain relief by blocking sodium channels in nerve membranes, which inhibits nerve impulse initiation and conduction.

Brand names: ZTlido
Other names: lidocaine topical system 1.8%

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine topical system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine topical system.

Explore the full profile